Advances in medical treatment of breast cancer in 2022

被引：16
作者：
Zhai, Jingtong [1 ]
Wu, Yun [1 ]
Ma, Fei [1 ]
Kaklamani, Virginia [2 ]
Xu, Binghe [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[2] UT Hlth San Antonio MD Anderson Canc Ctr, Div Hematol, Oncol, San Antonio, TX USA
来源：
CANCER INNOVATION | 2023年 / 2卷 / 01期
关键词：
breast cancer; chemotherapy; targeted therapy; endocrine therapy; immunotherapy; PHASE-II TRIAL; ABEMACICLIB PLUS TRASTUZUMAB; DERUXTECAN T-DXD; PATIENTS PTS; OPEN-LABEL; ENDOCRINE THERAPY; GIREDESTRANT GDC-9545; AROMATASE INHIBITOR; SURVIVAL OS; CHEMOTHERAPY;
D O I：
10.1002/cai2.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients. image
引用
收藏
页码：1 / 17
页数：17
相关论文
共 79 条
  • [1] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
    Allemani, Claudia
    Matsuda, Tomohiro
    Di Carlo, Veronica
    Harewood, Rhea
    Matz, Melissa
    Niksic, Maja
    Bonaventure, Audrey
    Valkov, Mikhail
    Johnson, Christopher J.
    Esteve, Jacques
    Ogunbiyi, Olufemi J.
    Azevedo e Silva, Gulnar
    Chen, Wan-Qing
    Eser, Sultan
    Engholm, Gerda
    Stiller, Charles A.
    Monnereau, Alain
    Woods, Ryan R.
    Visser, Otto
    Lim, Gek Hsiang
    Aitken, Joanne
    Weir, Hannah K.
    Coleman, Michel P.
    [J]. LANCET, 2018, 391 (10125) : 1023 - 1075
  • [2] Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
    Andre, F.
    Nadal, J. C.
    Denys, H.
    Goel, S.
    Litchfield, L. M.
    Appiah, A.
    Chen, Y.
    Tolaney, S. M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1386 - S1387
  • [3] Baek SY., 2022, J CLIN ONCOL, V40, DOI DOI 10.1200/JCO.2022.40.16_SUPPL.506
  • [4] Bardia A., 2022, SABCS
  • [5] Bardia A., 2022, Ann Oncol, V33, pS605, DOI DOI 10.1016/J.ANNONC.2022.07.179
  • [6] Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
    Barrios, Carlos H.
    Saji, Shigehira
    Harbeck, Nadia
    Zhang, Hong
    Jung, Kyung H.
    Patel, Sheetal
    Patel, Shilpen
    Anh Nguyen Duc
    Liste-Hermoso, Mario
    Chui, Stephen Y.
    Mittendorf, Elizabeth A.
    [J]. NPJ BREAST CANCER, 2022, 8 (01)
  • [7] Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
    Bartsch, R.
    Berghoff, A. S.
    Furtner, J.
    Marhold, M.
    Bergen, E. S.
    Roider-Schur, S.
    Starzer, A. M.
    Forstner, H.
    Rottenmanner, B.
    Dieckmann, K.
    Bago-Horvath, Z. A.
    Widhalm, G.
    Ilhan-Mutlu, A.
    Minichsdorfer, C.
    Fuereder, T.
    Singer, C. F.
    Weltermann, A.
    Puhr, R.
    Preusser, M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S198 - S198
  • [8] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Furtner, Julia
    Marhold, Maximilian
    Bergen, Elisabeth Sophie
    Roider-Schur, Sophie
    Starzer, Angelika Martina
    Forstner, Heidrun
    Rottenmanner, Beate
    Dieckmann, Karin
    Bago-Horvath, Zsuzsanna
    Haslacher, Helmuth
    Widhalm, Georg
    Ilhan-Mutlu, Aysegul
    Minichsdorfer, Christoph
    Fuereder, Thorsten
    Szekeres, Thomas
    Oehler, Leopold
    Gruenberger, Birgit
    Singer, Christian F.
    Weltermann, Ansgar
    Puhr, Rainer
    Preusser, Matthias
    [J]. NATURE MEDICINE, 2022, 28 (09) : 1840 - +
  • [9] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
    Bidard, Francois-Clement
    Kaklamani, Virginia G.
    Neven, Patrick
    Streich, Guillermo
    Montero, Alberto J.
    Forget, Frederic
    Mouret-Reynier, Marie-Ange
    Sohn, Joo Hyuk
    Taylor, Donatienne
    Harnden, Kathleen K.
    Khong, Hung
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick M.
    Babu, Sunil
    Waters, Simon
    Deleu, Ines
    Saenz, Jose A. Garcia
    Bria, Emilio
    Cazzaniga, Marina
    Lu, Janice
    Aftimos, Philippe
    Cortes, Javier
    Liu, Shubin
    Tonini, Giulia
    Laurent, Dirk
    Habboubi, Nassir
    Conlan, Maureen G.
    Bardia, Aditya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3246 - +
  • [10] Brain E, 2022, J CLIN ONCOL, V40
12345678